文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

伊匹木单抗联合全脑放疗或立体定向放射外科治疗黑色素瘤脑转移的1期研究

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-05-26

这项1期研究评估伊匹木单抗联合立体定向放射外科(SRS)或全脑放疗(WBRT)治疗黑色素瘤脑转移的最大耐受剂量与安全性。16例患者中,SRS联合伊匹木单抗10 mg/kg安全,WBRT组因入组缓慢提前关闭但伊匹木单抗3 mg/kg显示安全,均未出现剂量限制性毒性。

要点

  • SRS联合伊匹木单抗10 mg/kg未出现剂量限制性毒性,安全性可接受。
  • WBRT组因入组缓慢提前关闭,伊匹木单抗3 mg/kg显示安全。
  • 最常见3级毒性为胃肠道毒性(5例,31%),无4级或5级毒性。

核心结论

  • SRS同步伊匹木单抗10 mg/kg安全,WBRT联合伊匹木单抗3 mg/kg亦安全,均未观察到剂量限制性毒性。

研究设计与样本

  • 1期剂量递增研究,采用2阶段3+3设计,2011至2014年入组16例黑色素瘤脑转移患者。
  • 根据颅内疾病负荷分入WBRT组(A组,n=5)或SRS组(B组,n=11)。
  • 伊匹木单抗起始剂量3 mg/kg每3周,从WBRT第3天或SRS后2天开始,可递增至10 mg/kg。
  • 主要终点为伊匹木单抗联合放疗的最大耐受剂量,次要终点包括总生存、颅内和颅外控制、无进展生存及毒性。

主要发现

  • 16例患者平均年龄60岁,脑转移灶中位数2个(范围1至>10),13例(81%)有颅外疾病。
  • 伊匹木单抗3 mg/kg组7例,10 mg/kg组9例;中位随访A组8个月,B组10.5个月。
  • 共发生21例1至2级神经毒性,1例在伊匹木单抗给药前出现3级神经毒性。
  • 另报告10例3级毒性,最常见为胃肠道毒性(5例,31%),无4级或5级毒性。
  • A组中位无进展生存2.5个月、总生存8个月;B组中位无进展生存2.1个月、总生存未达到。

关键数值与推荐

  • 伊匹木单抗剂量递增至10 mg/kg联合SRS未出现剂量限制性毒性。
  • WBRT组伊匹木单抗3 mg/kg未出现剂量限制性毒性。
  • 3级胃肠道毒性发生率为31%(5/16)。

临床怎么用

  • 黑色素瘤脑转移患者可考虑SRS同步伊匹木单抗10 mg/kg治疗,需关注胃肠道毒性。
  • WBRT联合伊匹木单抗3 mg/kg可作为备选,但该组因入组缓慢提前关闭。

局限性

  • 样本量小(16例),WBRT组仅5例且提前关闭。
  • 随访时间较短,总生存数据不成熟(B组未达到)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a phase 1 study to determine the maximum tolerable dose and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiation therapy (WBRT) in patients with brain metastases from melanoma. METHODS AND MATERIALS: Based on the intracranial disease burden, patients underwent WBRT (arm A) or SRS (arm B). The ipilimumab starting dose was 3 mg/kg every 3 weeks, starting on day 3 of WBRT or 2 days after SRS. The ipilimumab dose was escalated to 10 mg/kg using a 2-stage, 3+3 design. The primary endpoint was to determine the maximum tolerable dose of ipilimumab combined with radiation therapy. The secondary endpoints were overall survival, intracranial and extracranial control, progression-free survival, and toxicity. The ClinicalTrials.gov registration number is NCT01703507. RESULTS: The characteristics of the 16 patients enrolled between 2011 and 2014 were mean age, 60 years; median number of brain metastases, 2 (range 1->10); and number with EC disease, 13 (81%). Treatment included WBRT (n=5), SRS (n=11), and ipilimumab 3 mg/kg (n=7) or 10 mg/kg (n=9). The median follow-up was 8 months (arm A) and 10.5 months (arm B). A total of 21 grade 1 to 2 neurotoxic effects occurred, with no dose-limiting toxicities. One patient experienced grade 3 neurotoxicity before ipilimumab administration. Ten additional grade 3 toxicities were reported, with gastrointestinal toxicities (n=5; 31%) the most common. No patient developed grade 4 or 5 toxicity. The median progression-free survival and overall survival in arm A was 2.5 months and 8 months and in arm B was 2.1 months and not reached, respectively. CONCLUSIONS: Concurrent ipilimumab 10 mg/kg with SRS is safe. The WBRT arm was closed early because of slow accrual but demonstrated safety with ipilimumab 3 mg/kg. No patient experienced dose-limiting toxicity. Larger studies, including those with combination checkpoint inhibitor therapy and SRS, are warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816150. doi:10.1016/j.ijrobp.2017.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。